TuHURA Biosciences (HURA)

About TuHURA Biosciences (HURA)

TuHURA Biosciences, Inc. is a clinical-stage immuno-oncology company, which engages in the development of novel technologies to overcome resistance to cancer immunotherapy. The firm’s lead product candidate, IFx2.0, is an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors. The company was founded on May 4, 2023 and is headquartered in Tampa, FL.

TuHURA Biosciences News